Bristol Consolidates Worldwide Pharmaceutical Operations
This article was originally published in The Pink Sheet Daily
Executive Summary
International President Andreotti is appointed worldwide pharmaceutical president; Americas President Hayden to depart in six months.
You may also be interested in...
Bristol/Merck's Pargluva Combination Use With Sulfonylureas Not Recommended
Committee supports use of the type 2 diabetes therapy muraglitazar as monotherapy and in combination with metformin, but says safety with sulfonylureas has not been adequately studied.
Bristol Orencia Pharmacovigilance Plan Sufficient For Approval, Committee Says
FDA's Arthritis Drugs Advisory Committee unanimously recommends approval of the rheumatoid arthritis therapy abatacept.
Bristol-Myers Squibb’s Hepatitis B Therapy Baraclude Will Be Available April 8
Entecavir clears FDA after a six-month priority review. Baraclude labeling includes data showing superior efficacy versus GlaxoSmithKline’s Epivir-HBV. Bristol will detail the product to the 3,500 physicians who treat most U.S. cases of hepatitis B using a Baraclude-specific sales force.